Search
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. … Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019.
Foreskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedOrcel, another skin substitute, is similar to Apligraf since it contains both fibroblasts and keratinocytes derived from neonatal foreskin, but in addition, utilizes a type I collagen sponge as its matrix … Apligraf has been useful in the treatment of venous leg ulcers and diabetic foot ulcers, by increasing rates of wound healing and decreasing the time required for closure of wounds [L2452].
Zinc gluconate
go.drugbank.com/drugs/DB11248ApprovedInvestigationalVet approvedZinc gluconate is a generally recognized as safe (GRAS) substance by FDA [L2081]. … suggest that administration of zinc along with new low osmolarity oral rehydration solutions/salts (oral rehydration solution), may reduce both the duration and severity of diarrheal episodes for up to
Mixtures: Super Daily No 2, Zinc and Algin Tab Nu LifeDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.
Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[L18438] Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc.[L18438] Remdesivir was also approved by the European Commission on July 3, 2020. … [L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020,[L13236] remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22
Hetacillin
go.drugbank.com/drugs/DB00739ApprovedVet approvedWithdrawnHetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin. … Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms.
Ramelteon
go.drugbank.com/drugs/DB00980ApprovedInvestigationalRamelteon has not been shown to produce dependence and has shown no potential for abuse. … Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN).
Ethinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnStructurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates … Nevertheless, the medication itself is generally no longer effective after using it for greater than 7 days.
Ansuvimab
go.drugbank.com/drugs/DB16385ApprovedHowever, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB … [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
Acute Myeloid Leukemia
go.drugbank.com/conditions/DBCOND0029883Drugs: Azacitidine · Cedazuridine · Cyclophosphamide · Cytarabine · Decitabine · Doxorubicin +9 moreSynonyms: Acute myeloid leukemia, no ICD-O subtype (morphologic abnormality), Acute myeloid leukemia, no International Classification of Diseases for Oncology subtype